New Technology May Help Fight Capsular Contracture
A new product may help prevent the formation of capsular contracture, a risk of breast augmentation that affects thousands of women across North America every year. The product, AIGISRx, helps by reducing inflammation and infection, thereby preventing the complication from happening.
One primary cause of capsular contracture is believed to be related to harmful bacteria forming biofilms inside the breast pocket, where the breast implant is located. Clinical trials conducted on animals showed that wrapping a breast implant with AIGISRx, a biodegradable antibiotic-impregnated sleeve, prior to placing it inside the body effectively treated all bacteria commonly linked with breast implant surgery – even more so than standard irrigation procedures. The product remains effective for about a month following surgery and it biodegrades safely within 3 months.
The breast implant may be placed completely inside the AIGISRx sleeve or placed on top if the implant is textured. The sleeve is a tyrosine-based polymer that has tetracycline- and rifamycin-derivative antibiotics.
Dr. William P. Adams Jr., a professor of plastic surgery at University of Texas Southwestern Medical Center in Dallas, leads the research and is currently seeking approval for AIGISRx from the FDA.
“We hope to make big progress with breast implant capsular contracture. This new technology will provide patients and surgeons with far better bacteria and biofilm coverage, and all one needs to do is simply place the product in the pocket and it is taken care of.”
- Posted in After Breast Augmentation, breast implants
- No Comments